Spironolactone in Diabetic Nephropathy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00317954

Enrollment

Registered

2006-04-25

Start date

2003-09-30

Completion date

2005-07-31

Last updated

2006-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Keywords

Diabetic nephropathy, Spironolactone, Aldosterone antagonism, Renoprotection

Brief summary

The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic patients with albuminuria despite recommended antihypertensive treatment.

Interventions

DRUGSpironolactone

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diabetes Mellitus * Diabetic Nephropathy * Glomerular filtration rate \> 30 ml/min/1.73 m2 * Blood pressure \> 130/80 mm Hg

Exclusion criteria

* Child bearing potential * Plasma-potassium \>4.5 mmol/l * Breastfeeding * Abuse of alcohol or drugs * Non-diabetic kidney disease

Design outcomes

Primary

Measure	Time frame
Changes in albuminuria	—
Changes in blood pressure	—

Secondary

Measure	Time frame
Changes in glomerular filtration rate	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026